Primary source: Safety monitoring and information
The indication for TRUQAP (capivasertib) has been updated to specify that it should only be used in patients with one or more PIK3CA, AKT1, or PTEN alterations.
This change ensures that TRUQAP is used in a manner that reflects the latest clinical findings, improving the benefit-risk balance for patients while reducing potential harm.
Regulatory teams must update product labeling to reflect the new indication and assess signal management considerations for capivasertib.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Regulatory teams must update product labeling to reflect the new indication and assess signal management considerations for capivasertib.
The TGA has approved an amendment to the indication for TRUQAP (capivasertib), now limiting its use to patients with PIK3CA, AKT1, or PTEN alterations based on new clinical data assessment.
What changed: The indication for TRUQAP (capivasertib) has been updated to specify that it should only be used in patients with one or more PIK3CA, AKT1, or PTEN alterations.
Why it matters: This change ensures that TRUQAP is used in a manner that reflects the latest clinical findings, improving the benefit-risk balance for patients while reducing potential harm.
Practical implication: Regulatory teams must update product labeling to reflect the new indication and assess signal management considerations for capivasertib.
Published from the regulator source ingestion pipeline after PV impact triage.
Monitor and evaluate the drug misuse trends and health impacts associated with ketamine, focusing on the increase in seizures as part of public health and law enforcement strategies.
Implement the updated product information by November 5, 2026, ensuring that all labeling and documentation includes the new warnings and risk profiles.
Implement new labeling requirements for choline salicylate products by November 5, 2026, including specific warnings as outlined.
The marketing authorization holder must submit amended product information reflecting the new safety guidelines by October 9, 2026, with translations due by August 10, 2026.
